THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of NHS Fife by:

Similar documents
Author of PGD: Adrian MacKenzie, Lead Pharmacist, Community Pharmacy.

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

Please call the Pharmacy Medicines Unit on or for a copy.

appropriate healthcare professionals employed at my pharmacy. I understand that I am

Minims Chloramphenicol

Job Title Name Signature Date

PRESCRIBING INFORMATION

November 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas

The active component of CHLOROMYCETIN eye ointment is chloramphenicol.

PRODUCT INFORMATION CHLORSIG

Submission for Reclassification

Package leaflet: Information for the user. GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin

New PGD. This direction was authorised on: Oct The direction will be reviewed by: Oct Author of PGD: Anne Duguid, Antimicrobial Pharmacist

PACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Patient Group Direction for METRONIDAZOLE (Version 03) Valid From 1 June May 2020

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

LABELLING AND PACKAGE LEAFLET

B. PACKAGE LEAFLET 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PGD previously approved: October This direction was authorised on: October The direction will be reviewed by: October 2019

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PROFESSIONAL PRACTICE STANDARD

Package leaflet: Information for the patient. FLUCLOXACILLIN 250MG/5ML ORAL SOLUTION Flucloxacillin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

New Zealand Consumer Medicine Information

B. PACKAGE LEAFLET 1

LABELLING AND PACKAGE LEAFLET A. LABELLING

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

notification of entry onto webpage Document Links

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET Page 1 of 6

SUMMARY OF PRODUCT CHARACTERISTICS

Delayed Prescribing for Minor Infections Resource Pack for Prescribers

SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET DYNA CEFPODOXIME 100 mg / DYNA CEFPODOXIME SUSPENSION:

Summary of Product Characteristics

Package leaflet: Information for the user

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

Collagen cross-linking after-care instructions

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children

PACKAGE LEAFLET: INFORMATION FOR THE USER. Amikacin 250 mg/ml Injection

Summary of Product Characteristics

1. WHAT CO-AMOXICLAV TABLETS IS AND WHAT IT IS USED FOR

GUIDE TO THE PROFESSIONAL PRACTICE STANDARD

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

Gentamicin or Tobramycin for Peritonitis in Peritoneal Dialysis

Acute Pyelonephritis POAC Guideline

Simplicef is Used to Treat Animals with Skin Infections

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

Summary of Product Characteristics

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

Developed By Name Signature Date

PACKAGE LEAFLET: INFORMATION FOR THE USER. AMOXICILLIN 250mg and 500mg CAPSULES BP Amoxicillin (as amoxicillin trihydrate)

Metacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.

SUMMARY OF PRODUCT CHARACTERISTICS

2 What you need to know before you take Augmentin

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

Package leaflet: Information for the patient. Co-amoxiclav 500 mg/125 mg film-coated tablets. amoxicillin/ clavulanic acid

Amoxicillin 250mg Hard Capsules Amoxicillin 500mg Hard Capsules

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

EXCEDE Sterile Suspension

PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION

Fish will normally be starved for 24 hours ahead of treatment. The starvation period may be varied on veterinary advice.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

V E T E R I N A R Y C O U N C I L O F I R E L A N D ETHICAL VETERINARY PRACTICE

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SHARED CARE GUIDELINE FOR GLYCOPYRROLATE 1. Aim/Purpose of this Guideline

GUIDANCE FOR VETERINARY SURGEONS. Use of norethisterone for oestrus suppression in racing bitches in Great Britain

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

SUMMARY OF PRODUCT CHARACTERISTICS

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

See Important Reminder at the end of this policy for important regulatory and legal information.

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

Metacam 1.5 mg/ml oral suspension for dogs

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

The College of Veterinarians of Ontario. Guidelines. for the Compounding of Veterinary Drugs

SUMMARY OF PRODUCT CHARACTERISTICS

Consider the patient, the drug and the device how do you choose?

Summary of Product Characteristics

Treatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

Package leaflet: Information for the patient. Co-amoxiclav 250 mg/125 mg film-coated tablets Amoxicillin/clavulanic acid

Transcription:

Patient Group Direction for Named Community Pharmacists to Supply CHLORAMPHENICOL EYE DROPS 0.5% To patients aged 1 year and older Under the Minor Ailments Service. Number 114 Issued October 2016 Issue Number 5 Date of review* October 2019 First Issued July 2006 * If this PGD is past its review date then the content will remain valid until such time as the PGD review is complete and the new issue published It is the responsibility of the person using this PGD to ensure that they are using the most recent issue. This can be found on the Intranet at http://intranet.fife.scot.nhs.uk Developed by Designation Signature Date Margery Reid PGD Pharmacist 19.09.16 Dr Drew Smart Dr David Griffith Medical Director Primary Care Emergency Service Consultant Microbiologist 21.09.16 22.09.16 THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of by: Name Designation Signature Date Janette Owens Associate Nurse Director 29.09.16 Dr Seonaid McCallum Associate Medical Director 01.11.16 Andrea Smith Lead Pharmacist Pharmacy Services 28.09.16 Issue 5 Page 1 of 5

1. Clinical condition to which the patient group direction applies Indication Conjunctivitis will give the sensation of a gritty or itchy eye or eyes, with possibly a purulent discharge or crusting of the eyelid margins. It will only have been present for a few days and is not associated with any reduction in vision. The affected eye(s) will often look slightly red/infected, but this is not usually very marked. Pain is not a feature of simple conjunctivitis Inclusion criteria Adults and children 1 year and over. Presentation in Community Pharmacy with a need for of symptoms of bacterial conjunctivitis, and registered for the Minor Ailment Service (MAS). Informed consent to obtained Exclusion criteria Referral Criteria Patient not eligible for MAS Children under 1 year old Pregnancy Breast-feeding Known hypersensitivity to chloramphenicol or any excipient in the drops. (Consult Summary of Product Characteristics (SPC) or manufacturer s Patient Information Leaflet (PIL). Family history of blood dyscrasias Myelosupression during previous exposure Consent to refused Urgent referral: - severe pain within the eye, rather than itchy or gritty - reduced visual acuity or disturbed vision - eye inflammation associated with a rash on the scalp or face - the eye looks cloudy - the pupil looks unusual - photophobia - if pus level visible in anterior chamber - if any history of trauma to eye immediately prior to onset of symptoms - if possibility of foreign body on/in eye - if no improvement within 48 hours Routine referral: - pregnancy - breast feeding - previous conjunctivitis in the recent past - glaucoma - dry eye syndrome - eye surgery or laser in the last 6 months - current use of other eye drops or eye ointment Action if excluded Action if patient declines Do not use the PGD The patient must be referred to a doctor. The reason for referral should be documented The patient must be referred to a doctor. The reason for refusal should be documented Ensure awareness of implications of declining Issue 5 Page 2 of 5

2. Medication details Name strength Chloramphenicol 0.5% Eye Drops & formulation of drug Route of Topically to the eye/s administration Dosage Adults and children 1 year and over Apply 1 drop at least every 2 hours for 2 days then reduce frequency to every 4 hours during waking hours as infection is controlled, and continue for 48 hours after symptoms resolve to a maximum of 5 days. NB Chloramphenicol 1% ointment may also be supplied for use at night see PGD 190 Frequency of As above in Dose/Dose Range administration Duration of Quantity to be supplied Patient advice verbal and written As above in Dose/Dose Range To continue for 48 hours after symptoms resolve to a maximum of 5 days One 10ml bottle of Chloramphenicol 0.5% Eye Drops for each infected eye. Label for RIGHT and for LEFT eye. The patient information leaflet should be given. Contact lenses should be removed during period of. Continue for at least 48 hours after the eye appears normal. Store in a fridge (between 2-8º), and keep cap tightly closed between applications. Remove from fridge 10 minutes before use to allow solution to warm slightly. Use the bottle labelled for each affected eye to avoid transferring infection. Try not to touch the eye or lashes with the nozzle as this may transfer infection. Do not reuse supply for another episode of conjunctivitis Blurring may occur. Patients should be warned not to drive or operate machinery unless vision is clear. Discard 28 days after opening. Advise patient that if condition worsens or if no sign of improvement within 48 hours they should seek further medical advice Legal category Prescription Only Medicine Storage requirements Identification and management of adverse reactions Additional facilities/ supplies required Store in a refrigerator between 2 and 8 o C. Protect from light. Ensure within expiry date Occasional: Transient stinging on instillation. Rare: Allergic reaction (persistent burning, swelling of lids) There have been rare reports of aplastic anaemia. However, the BNF states that chloramphenicol eye drops are well tolerated and the recommendation that chloramphenicol eye drops should be avoided because of an increased risk of aplastic anaemia is not well founded. Advise patient to seek medical advice for significant side effects or if concerned All suspected serious reactions should be reported directly to the MHRA/Commission on Human Medicines through the Yellow Card scheme and recorded in the patient s medical notes. Reports should be made online at www.mhra.gov.uk/yellowcard.. Advice may be obtained from Yellow Card Centre Scotland on 0131 242 2919 Access to a BNF/ BNFc Issue 5 Page 3 of 5

3. Staff characteristics Professional qualifications Specialist competencies or qualifications Continued training requirements Pharmacist with current General Pharmaceutical Council registration Registered Pharmacist competent to undertake supply of medicines under Patient Group Directions. It is the responsibility of the named community pharmacist using this PGD to ensure that with the drug detailed in this direction is appropriate. If in any doubt, advice should be sought and recorded before the preparation is supplied Updates on the management of conjunctivitis when appropriate Maintains own professional level of competence and knowledge in this area. Keep up-to-date with information on contraindications, cautions and interactions for Chloramphenicol Eye Drops from the BNF, SPC and PIL and refer to a doctor if necessary 4. Referral arrangements/audit trail Arrangements for referral to medical advice Records/Audit trail The patient may be referred to a doctor at any stage, if this is necessary, in the professional opinion of the pharmacist. Patients should be referred to a doctor if proves to be ineffective in relieving the symptoms The approved practitioner must ensure maintenance of records for each supply and may be required to share information with appropriate parties in line with confidentiality protocols.the information relating to the supply of medication of each individual must include as a minimum in the computerised patient information records and on the CP 2 form: Patient s name and date of birth CHI number if available Dose Brand, batch number and expiry date of medicine, Date given and by whom. All records must be clear and legible and, ideally, in an easily retrievable format. Depending on the clinical setting where the supply of medication is undertaken, the information should be recorded manually or electronically, in one (or more) of the following systems, as appropriate: GP practice computer, Individuals GP records. Pharmacy Record and or PMR References/ Resources & comments BNF / BNFc latest edition available at www.medicinescomplete.org Summary of Product Characteristics Chloramphenicol 0.5% eyedrops available at www.medicines.org.uk Antibiotic Guidance for Management of Common Infections 2010. Issue 5 Page 4 of 5

This Patient Group Direction has been assessed for Equality and Diversity Impact 5. Management and monitoring of Patient Group Direction Pharmacist Agreement Supply of Chloramphenicol Eye Drops 0.5% by Community Pharmacists I, confirm that I have read and understood the above Patient Group Direction. I confirm that I have the necessary professional registration, competence, and knowledge to apply the Patient Group Direction. I will ensure my competence is updated as necessary. I will have ready access to a copy of the Patient Group Direction in the clinical setting in which the supply of the medicine will take place and agree to provide this medicine only in accordance with this PGD. I understand that it is the responsibility of the pharmacist to act in accordance with the Code of Ethics for Pharmacists and to keep an up to date record of training and competency. Name of Pharmacist GPharm Council Registration No. Usual Pharmacy Location Signature Date Note: A copy of this agreement must be signed by each pharmacy practitioner who wishes to be authorised to use the PGD for the supply of Chloramphenicol Eye drops under MAS. Please fax a copy of this page to Pharmacy services on 01383 741395 Each authorised pharmacy practitioner should be provided with an individual copy of the authorised PGD. Issue 5 Page 5 of 5